GLOBAL — 04 09
Beyond Symptom Relief: How XyliMelts' Clinical Study Reveals the Sleep-Dry Mouth Market Opportunity
A recent clinical study on Orasana's XyliMelts, showing 80% symptom reduction and 75% improved sleep quality, is more than a product validation. It illuminates a significant, underserved market at the intersection of oral care and sleep health. This analysis explores how the study's design and results reveal a strategic shift from treating dry mouth as a daytime nuisance to a nighttime wellness issue, creating a new product category. We examine the economic logic of OTC adherence technology, the potential long-term impact on consumer behavior and supply chains, and why this signals a broader trend in preventative, self-managed health solutions.